Currently out of the existing stock ratings of Debjit Chattopadhyay, 184 are a BUY (91.54%), 17 are a HOLD (8.46%).

Debjit Chattopadhyay

Work Performance Price Targets & Ratings Chart

Analyst Debjit Chattopadhyay, currently employed at GUGGENHEIM, carries an average stock price target met ratio of 50.55% that have a potential upside of 35.13% achieved within 287 days.

Debjit Chattopadhyay’s has documented 412 price targets and ratings displayed on 40 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on RZLT, Rezolute at 12-Dec-2025.

Wall Street Analyst Debjit Chattopadhyay

Analyst best performing recommendations are on HARP (HARPOON THERAPEUTICS).
The best stock recommendation documented was for MGNX (MACROGENICS) at 5/6/2020. The price target of $22 was fulfilled within 1 day with a profit of $3.15 (12.52%) receiving and performance score of 125.25.

Average potential price target upside

QURE Uniqure NV SRPT Sarepta Therapeutics BEAM Beam Therapeutics  BLUE Bluebird bio CLVS Clovis Oncology IONS Ionis Pharmaceuticals NTLA Intellia Therapeutics TSHA Taysha Gene Therapies  PASG Passage Bio BMRN Biomarin Pharmaceutical KRYS Krystal Biotech VRTX Vertex Pharmaceuticals CNTA Centessa Pharmaceuticals PLC ADR ALLO Allogene Therapeutics AUTL Autolus Therapeutics Ltd BOLD Audentes Therapeutics GBT Global Blood Therapeutics GLPG Galapagos NV ADR HARP Harpoon Therapeutics IMGN ImmunoGen JNCE Jounce Therapeutics SLNO Soleno Therapeutics MGNX MacroGenics MRSN Mersana Therapeutics VYGR Voyager Therapeutics NKTR Nektar Therapeutics DTIL Precision BioSciences BCYC Bicycle Therapeutics Ltd BNTC Benitec Biopharma Ltd ADR DYN Dyne Therapeutics  FATE Fate Therapeutics FOLD Amicus Therapeutics RZLT Rezolute WVE Wave Life Sciences Ltd PRME Prime Medicine, Common Stock SMMT Summit Therapeutics PLC DARE Dare Bioscience NEO NeoGenomics RARE Ultragenyx ZYME Zymeworks Common Stock

Analyst name

Rating

Rating initiation date

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy

Since 01-Apr-2025

$53

$29.61 (126.59%)

$53

1 months 2 days ago
(04-Dec-2025)

6/9 (66.67%)

$27.52 (108.01%)

102

Buy

Since 25-Sep-2025

$60

$36.61 (156.52%)

$80

1 months 25 days ago
(12-Nov-2025)

3/5 (60%)

$29.88 (99.20%)

116

Buy

Since 10-May-2023

$45

$21.61 (92.39%)

$24

2 months 2 days ago
(04-Nov-2025)

7/8 (87.5%)

$10.71 (31.23%)

443

Hold

Since 29-Feb-2024

$38

$14.61 (62.46%)

$56

2 months 2 days ago
(04-Nov-2025)

7/9 (77.78%)

$3.71 (10.82%)

263

Buy

Since 25-Sep-2025

$60

$36.61 (156.52%)

$20

3 months 12 days ago
(25-Sep-2025)

5/5 (100%)

$7.35 (13.96%)

138

Show more analysts

Please expand the browser size to see the chart

Which stock is Debjit Chattopadhyay is most bullish on?

Potential upside of $93.87 has been obtained for VRTX (VERTEX PHARMACEUTICALS)

Which stock is Debjit Chattopadhyay is most reserved on?

Potential downside of -$1.69 has been obtained for PASG (PASSAGE BIO)

What Year was the first public recommendation made by Debjit Chattopadhyay?

On 2014

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?